Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD0901 + AZD2936 + Fluorouracil |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD0901 | AZD-0901|AZD 0901|CMG901|CM-G901|CM G901 | CLDN18.2 Antibody 23 | AZD0901 is an antibody-drug conjugate (ADC) comprising an anti-CLDN18.2 antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which may induce antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth (PMID: 39232496). | |
| AZD2936 | AZD-2936|AZD 2936|Rilvegostomig | PD-L1/PD-1 antibody 134 TIGIT Antibody 20 | AZD2936 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-1 (PDCD1), which potentially leads to increased T-lymphocyte antitumor activity, tumor cell killing, and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). | |
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07069712 | Phase II | AZD2936 + Fluorouracil + Trastuzumab deruxtecan AZD2936 + Capecitabine + Trastuzumab deruxtecan AZD0901 + AZD2936 + Capecitabine AZD2936 + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin AZD0901 + AZD2936 + Fluorouracil | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | Recruiting | USA | TUR | POL | ITA | GBR | ESP | CAN | 4 |